Venous Wall of Patients with Chronic Venous Disease Exhibits a Glycolytic Phenotype

• Published in: Journal of personalized medicine Vol. 12; no. 10; p. 1642
• Main Authors: Fraile-Martinez, Oscar, García-Montero, Cielo, Alvarez-Mon, Miguel Ángel, Gomez-Lahoz, Ana M., Monserrat, Jorge, Llavero-Valero, Maria, Ruiz-Grande, Fernando, Coca, Santiago, Alvarez-Mon, Melchor, Buján, Julia, García-Honduvilla, Natalio, Saz, Jose V., Ortega, Miguel A.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 03.10.2022; MDPI
• Subjects: Antibodies; chronic venous disease (CVeD); Dehydrogenases; Gene expression; Glucose; Glucose transporter; Glycolysis; glycolytic phenotype; histopathological markers; Hypertension; Hypoxia; Kinases; Laboratories; Metabolism; Patients; Phenotypes; Precision medicine; Protein expression; Protein transport; Statistical analysis; varicose veins (VVs); Veins & arteries; Womens health; United States > US
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm12101642

Chronic venous disease (CVeD) is a rising medical condition characterized by a broad spectrum of disorders in the venous system. Varicose veins (VVs) represent a frequent clinical manifestation of CVeD, particularly in the lower limbs. Prior histopathological studies have defined a set of alterations observed in the venous wall of patients with VVs, affecting their structure and behavior. Metabolic changes in the veins appear to be a critical biological mechanism aiding our understanding of the pathogenesis of CVeD. In this sense, previous studies have identified a potential role of a glycolytic phenotype in the development of different vascular disorders; however, its precise role in CVeD remains to be fully explored. Thus, the aim of the present study was to analyze the gene and protein expression of glucose transporter 1 (GLUT-1) and the glycolytic enzymes PGK-1, ALD, GA3PDH and LDH in the VVs of patients with CVeD (n = 35) in comparison to those expressed in healthy subjects. Our results display enhanced gene and protein expression of GLUT-1, PGK-1, ALD, GA3PDH and LDH in patients with CVeD, suggesting a glycolytic switch of the venous tissue. Greater understanding of the impact of this glycolytic switch in patients with CVeD is required to define a possible pathophysiological role or therapeutic implications of these changes.